Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Cecilia, Mur"'
Autor:
Raquel, Torres-Guzmán, Maria Patricia, Ganado, Cecilia, Mur, Carlos, Marugan, Carmen, Baquero, Yanzhu, Yang, Yi, Zeng, Huimin, Bian, Jian, Du, Alfonso, de Dios, Oscar, Puig, María José, Lallena
Publikováno v:
Oncotarget. 13:864-875
Abemaciclib is an oral, selective cyclin-dependent kinase 46 inhibitor (CDK46i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) as monotherapy for endocrine refract
Autor:
Jennifer R. Stephens, Sean Buchanan, Farhana F. Merzoug, Manisha Brahmachary, Ann M. McNulty, Lacey M. Litchfield, Xiang S. Ye, Karsten Boehnke, Xueqian Gong, Wenjuan Wu, Valerie M. Jansen, J. Michael Sauder, Chen Bi, Sonia M Gutiérrez, Maria Jose Lallena, Cecilia Mur
Publikováno v:
Oncotarget
Aberrant activation of mitogenic signaling pathways in cancer promotes growth and proliferation of cells by activating mTOR and S6 phosphorylation, and D-cyclin kinases and Rb phosphorylation, respectively. Correspondingly, inhibition of phosphorylat
Autor:
Raquel Torres-Guzmán, Carmen Baquero, Alfonso De Dios, Yi Zeng, Maria Jose Lallena, Maria Patricia Ganado, Cecilia Mur, Carlos Marugán, Yanzhu Yang, Oscar Puig, Jian Du, Huimin Bian
Abemaciclib is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor (CDK4 & 6i), approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) as monotherapy for endocrine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ddd2ccf15e36d11d977f8cb9e51129e
https://doi.org/10.1101/2021.11.15.468648
https://doi.org/10.1101/2021.11.15.468648
Autor:
Dongling Fei, Weihua Shen, Shripad V. Bhagwat, Mark A. Castanares, Brian E. Mattioni, Sheng-Bin Peng, Cecilia Mur, Lisa Kindler, Almudena Rubio, Alfonso De Dios, Jolie Anne Bastian, Baohui Zhao, Thomas K. Baker, Robert J. Barr, Maria Jose Lallena, Jason Manro, Eunice Yuen, Jeffrey Daniel Cohen
Publikováno v:
Cancer Research. 81:1236-1236
Nearly 70% of newly diagnosed breast cancers are estrogen receptor alpha (ERα) positive, for which endocrine therapy is a primary treatment. However, approximately 40% of those patients on endocrine therapy develop resistance, which includes mutatio
Autor:
Swee Seong Wong, Michele Dowless, Alfonso De Dios, Chen Bi, Xueqian Gong, Richard P. Beckmann, Carlos Marugán, Yi Zeng, Xiang S. Ye, Li-Chun Chio, Lacey M. Litchfield, Farhana F. Merzoug, Jack A. Dempsey, Shaoyou Chu, Hui-Rong Qian, Christoph Reinhard, Karsten Boehnke, Trent R. Stewart, Yue Webster, Maria Jose Lallena, Cecilia Mur, Sean Buchanan, Isabella H. Wulur, Charles W. Caldwell, Steven M. Bray, Jian Du, Chunping Yu, Philip W. Iversen, Raquel Torres, Carmen Baquero
Publikováno v:
Cancer Cell. 32:761-776.e6
Summary Most cancers preserve functional retinoblastoma (Rb) and may, therefore, respond to inhibition of D-cyclin-dependent Rb kinases, CDK4 and CDK6. To date, CDK4/6 inhibitors have shown promising clinical activity in breast cancer and lymphomas,
Publikováno v:
Endocrinology. 144:581-593
To define the specific role of IGF-I receptor (IGF-IR) in adipogenic and thermogenic differentiation of brown adipocytes during late fetal life, we have established immortalized brown adipocyte cell lines from fetuses of IGF-IR-deficient mice (IGF-IR
Autor:
Philip W. Iversen, Cecilia Mur, Karsten Boehnke, Carmen Baquero, Severine I. Gharbi, Carlos Marugán, Xueqian Gong, Alfonso deDios, Sandra Gomez, Richard Beckman, Sean Buchanan, Maria Jose Lallena, Raquel Torres-Guzmán, Joaquín Amat
Publikováno v:
Cancer Research. 77:LB-318
Lung cancer is the most common tumor cancer worldwide and approximately 15-25% of the patients with lung adenocarcinoma have KRAS driven tumors. These malignancies involve, in the majority of cases, a constitutive activation of KRAS signaling pathway
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
In the present study we have investigated the effect of increased serine/threonine phosphorylation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) by okadaic acid pretreatment on brown adipocyte insulin signalling leading to glucose transpo
Autor:
Ana Hermoso, Bruna Calsina, Sean Buchanan, Cecilia Mur, Xueqian Gong, Karsten Boehnke, Carmen Baquero, Joaquín Amat, Richard P. Beckmann, Alfonso De Dios, Raquel Torres, Maria Jose Lallena
Publikováno v:
Cancer Research. 76:2836-2836
Breast cancer is the second most common cancer worldwide after lung cancer. About 70% of breast cancers express estrogen receptor α (ER+) and/or progesterone receptor (PR+), and these biomarkers are indicative of hormone dependence. However up to 50
Fetal brown adipocytes are insulin-like growth factor-I (IGF-I) target cells. To assess the importance of the IGF-I receptor (IGF-IR) in brown adipocytes during fetal life, we have generated immortalized brown adipocyte cell lines from the IGF-IR-/-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc5c42c9809f72b3f5f7575a2fcaaff
https://europepmc.org/articles/PMC524782/
https://europepmc.org/articles/PMC524782/